30 closest matches · ranked by relevance
Primary Sclerosing Cholangitis
Primary: Number of Participants With Treatment Emergent Adverse Events — 21; 10; 16; 15 Participants
Primary Sclerosing Cholangitis
Primary: Change in Serum Alkaline Phosphatase (SAP) — 3 Participants — p=.03
Primary Sclerosing Cholangitis (PSC)
Primary: Change From Baseline in MQC on Liver Biopsy at Week 96 — -0.5; 0.5; 0.0 percentage of MQC
Sclerosing Cholangitis
Primary: Adverse Event Frequency — 8 Participants
Primary Sclerosing Cholangitis
Primary: Percentage of Participants Experiencing Treatment-Emergent Adverse Events During the Blinded Phase — 81.8; 70.0; 100.0 percentage of participants
Primary Sclerosing Cholangitis (PSC)
Primary: DB Phase: Change From Baseline In Serum Alkaline Phosphatase (ALP) — -105.05; -110.19; -26.76 U/L — p=0.0434
Primary Sclerosing Cholangitis
Primary: Count of Participants With Elevated Alanine Aminotransferase (ALT) at Baseline and With Clinically Significant Improvement at Month 3 — 10; 6 Participants
Primary Sclerosing Cholangitis
Primary: Mean Change From Baseline in Alkaline Phosphatase in Patients With Primary Sclerosing Cholangitis — 25.6; -9.8; -0.6 International units/Liter — p=0.434
Pruritus
Primary: Change From Baseline in the Worst Itch Numeric Rating Scale (WI-NRS) Score up to Week 6 — -2.20; -1.75 scores on a scale — p=0.4577
Primary Biliary Cholangitis · Cardiovascular Abnormalities
Primary: The Incidence of Cardiac Events — 0; 0; 0; 0 Participants — p=0.001
Primary Biliary Cholangitis · Liver Stiffness
Primary: Change in ALP at Week 24 Compared to Baseline — 0.89; 0.84; 1.03 ratio — p=0.0206
Primary Sclerosing Cholangitis
Primary: Percentage Change From Baseline Through Week 24 in Serum Alkaline Phosphatase (ALP) — -4.5 percentage change in ALP
Primary Sclerosing Cholangitis
Primary: Subjects Who Experience a Positive Outcome as Measured by Combination of Serum Alkaline Phosphatase (ALP) and Aspartate Aminotransferase (AST) Levels. — 3 Participants
Primary Sclerosing Cholangitis
Primary: Change From Baseline in Alkaline Phosphatase Following 12 Weeks of Treatment — -117; -49; -62; -36 U/L
Primary Sclerosing Cholangitis (PSC)
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 1; 2; 2; 1 participant
Biliary Stricture
Primary: Feasibility of Imaging the Bile Duct With the OFDI Probe — 7 Participants
Primary Biliary Cirrhosis
Primary: The Percent Change in Serum GGT. — -4.9; -19; -8.4 percent change
Primary Biliary Cirrhosis
Primary: Part 1: Number of Participants With Alkaline Phosphatase (ALP) Response at Week 12 — 0 participants
Primary Biliary Cholangitis
Primary: Percentage of Participants With At Least a 20% Reduction in Alkaline Phosphatase (ALP) or Normalization of ALP at Week 12 Compared to Baseline — 45.2; 46.4; 11.1…
Primary Biliary Cirrhosis
Primary: Change in Serum Alkaline Phosphatase Levels. — -57.3 U/L — p=0.001
Primary Biliary Cirrhosis
Primary: Relative Change From Baseline in Serum Alkaline Phosphatase (ALP) at Week 8 — -26.06; -33.38; -41.42 percentage change from baseline — p== 0.2242
Primary Biliary Cholangitis
Primary: Percentage of Participants With Response Criteria for the Composite Endpoint of ALP <1.67 × Upper Limit of Normal (ULN), ≥15% Reduction in ALP, and Total Bilirubin ≤…
Primary Biliary Cholangitis
Primary: Percentage of Participants With Response to Composite Endpoint of ALP <1.67 × Upper Limit of Normal [ULN], ≥15% Reduction in ALP, and Total Bilirubin ≤ ULN) at Month 3…
Primary Biliary Cirrhosis
Primary: Effect of a 16-week Treatment Regimen of Saroglitazar Magnesium 2 mg and 4 mg on Alkaline Phosphatase (ALP) Levels in Patients With Primary Biliary Cholangitis…
Primary Sclerosing Cholangitis · Biliary Atresia
Primary: Determine the Benefit of Oral Vancomycin Therapy for Primary Sclerosing Cholangitis and Biliary Atresia — 10; 0; 0; 0 participants
Primary Biliary Cirrhosis
Primary: DB Phase: Composite Endpoint Alkaline Phosphatase (ALP) And Total Bilirubin, 10 mg OCA Versus Placebo — 47; 10 percentage of participants — p=<0.0001
Primary Biliary Cholangitis (PBC)
Primary: Relative Change From Baseline in Serum Alkaline Phosphatase (ALP) Levels at Week 12 (Endpoint) — -48.264; -40.640; 3.190 Percent change — p=<0.001
Primary Biliary Cirrhosis
Primary: Biochemical Response — 1 Participants
Primary Biliary Cholangitis
Primary: Fold Change in Serum Gamma-glutamyl Transferase (GGT) — 0.74; 0.41; 0.28; 0.31 fold-change — p=0.293
Primary Biliary Cirrhosis
Primary: Number of Participants With Adverse Events — 1; 3; 2 Participants